Sanofi receives FDA orphan drug designation for riliprubart in transplant rejection

Hoth Therapeutics reports positive interim results for HT-001 topical therapy

Breckenridge Pharmaceutical's generic for Ablysinol granted final FDA approval

Hemab Therapeutics presents bleeding disorder clinical and preclinical data at ISTH 2025 Congress

PTC Therapeutics receives European marketing authorisation for sepiapterin in phenylketonuria treatment

Cumberland Pharmaceuticals reports ifetroban Phase 2 DMD heart disease trial results

Sarclisa recommended for EU approval in newly diagnosed transplant-eligible multiple myeloma

Hyloris partners with Kuvatris to advance Suramin IV for sleeping sickness and pursue Priority Review Voucher

European Commission approves argenx's VYVGART subcutaneous injection with Halozyme's ENHANZE for CIDP

FDA approves Dupixent as first targeted therapy for rare skin disease bullous pemphigoid

Dizal completes enrolment in sunvozertinib vs. platinum doublet phase III study

GRAIL reports positive results from Galleri multi-cancer early detection test registrational study

Simcere Zaiming reports first patient dosed in SIM0500 US Phase 1 trial in patients with relapsed/refractory multiple myeloma

FDA approval of Keytruda sets positive regulatory precedent for CEL-SCI's Multikine in PD-L1 negative head and neck cancer

Bavarian Nordic sells US Priority Review Voucher for USD160m